An immediate intravesical instillation of mitomycin C is of benefit in all prognostic risk groups with non-muscle-invasive bladder cancers.
作者信息
Oosterlinck Willem, Decaestecker Karel
机构信息
Department of Urology, Ghent University Hospital, Ghent, Belgium.
出版信息
Transl Androl Urol. 2018 Dec;7(Suppl 6):S706-S709. doi: 10.21037/tau.2018.10.07.
Abstract
摘要
相似文献
1
An immediate intravesical instillation of mitomycin C is of benefit in all prognostic risk groups with non-muscle-invasive bladder cancers.对于所有非肌层浸润性膀胱癌的预后风险组，即刻膀胱内灌注丝裂霉素C是有益的。
Transl Androl Urol. 2018 Dec;7(Suppl 6):S706-S709. doi: 10.21037/tau.2018.10.07.
2
An immediate, single intravesical instillation of mitomycin C is of benefit in patients with non-muscle-invasive bladder cancer irrespective of prognostic risk groups.对于非肌层浸润性膀胱癌患者，无论预后风险分组如何，立即进行单次膀胱内丝裂霉素C灌注均有益处。
Urol Oncol. 2018 Sep;36(9):400.e7-400.e14. doi: 10.1016/j.urolonc.2018.05.026. Epub 2018 Jul 29.
3
Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients.表柔比星联合顺铂膀胱灌注化疗预防膀胱癌术后复发的多中心随机对照研究
表柔比星联合顺铂膀胱灌注化疗预防膀胱癌术后复发的多中心随机对照研究
表柔比星联合顺铂膀胱灌注化疗预防膀胱癌术后复发的多中心随机对照研究
表柔比星联合顺铂膀胱灌注化疗预防膀胱癌术后复发的多中心随机对照研究
Eur Urol. 2018 Feb;73(2):226-232. doi: 10.1016/j.eururo.2017.06.038. Epub 2017 Jul 10.
4
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.电渗滴注丝裂霉素即刻经尿道膀胱肿瘤切除术治疗原发性非肌层浸润性膀胱尿路上皮癌患者：一项随机对照试验。
Lancet Oncol. 2011 Sep;12(9):871-9. doi: 10.1016/S1470-2045(11)70190-5. Epub 2011 Aug 8.
5
Impact of age on outcomes of patients with non-muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C.年龄对术后即刻膀胱灌注丝裂霉素C治疗的非肌层浸润性膀胱癌患者预后的影响
Urol Oncol. 2018 Mar;36(3):89.e1-89.e5. doi: 10.1016/j.urolonc.2017.11.010. Epub 2017 Dec 6.
6
[Guidelines for good practice of intravesical instillations of BCG and mitomycin C from the French national cancer committee (CC-AFU) for non-muscle invasive bladder cancer].[法国国家癌症委员会（CC-AFU）关于非肌层浸润性膀胱癌卡介苗和丝裂霉素C膀胱灌注良好实践指南]
Prog Urol. 2012 Nov;22(15):920-31. doi: 10.1016/j.purol.2012.05.002. Epub 2012 Jun 15.
7
[Value of European Organisation for Research and Treatment of Cancer score system for predication of immediate postoperative intravesical instillation of pirarubicin after transurethral resection of non-muscle invasive bladder cancer].[欧洲癌症研究与治疗组织评分系统对非肌层浸润性膀胱癌经尿道切除术后即刻膀胱内灌注吡柔比星预测的价值]
Zhonghua Zhong Liu Za Zhi. 2018 Apr 23;40(4):308-312. doi: 10.3760/cma.j.issn.0253-3766.2018.04.014.
8
Risk of post-operative intravesical mitomycin C instillation following transurethral bladder tumor resection.经尿道膀胱肿瘤切除术后膀胱内灌注丝裂霉素C的风险
Can J Urol. 2006 Dec;13(6):3317-20.
9
The effect of timing of an immediate instillation of mitomycin C after transurethral resection in 941 patients with non-muscle-invasive bladder cancer.941 例非肌层浸润性膀胱癌经尿道切除术后即刻应用丝裂霉素 C 灌洗的时间效应。
BJU Int. 2018 Oct;122(4):571-575. doi: 10.1111/bju.14124. Epub 2018 Jan 31.
10
[Assessment of the optimization of the conditions of mitomycin C intravesical instillation completion in the setting of non-muscle invasive bladder cancer treatment].[非肌层浸润性膀胱癌治疗中丝裂霉素C膀胱内灌注完成条件的优化评估]
Prog Urol. 2016 Feb;26(2):79-82. doi: 10.1016/j.purol.2015.10.005. Epub 2015 Nov 30.
引用本文的文献
1
Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Abridged version.加拿大泌尿外科协会非肌层浸润性膀胱癌管理指南 - 简版
Can Urol Assoc J. 2021 Aug;15(8):230-239. doi: 10.5489/cuaj.7487.
2
Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Full-text.加拿大泌尿外科协会非肌层浸润性膀胱癌管理指南 - 全文
Can Urol Assoc J. 2021 Aug;15(8):E424-E460. doi: 10.5489/cuaj.7367.
本文引用的文献
1
An immediate, single intravesical instillation of mitomycin C is of benefit in patients with non-muscle-invasive bladder cancer irrespective of prognostic risk groups.对于非肌层浸润性膀胱癌患者，无论预后风险分组如何，立即进行单次膀胱内丝裂霉素C灌注均有益处。
Urol Oncol. 2018 Sep;36(9):400.e7-400.e14. doi: 10.1016/j.urolonc.2018.05.026. Epub 2018 Jul 29.
2
Editorial on the value of an immediate intravesical instillation of mitomycin C in patients with non-muscle-invasive bladder cancer.
Transl Androl Urol. 2018 Mar;7(Suppl 1):S135-S137. doi: 10.21037/tau.2017.09.20.
3
Update on early instillation of chemotherapy after transurethral resection of non-muscle-invasive bladder cancer.经尿道膀胱肿瘤切除术（非肌层浸润性膀胱癌）后早期膀胱内化疗的最新进展。
Expert Rev Anticancer Ther. 2018 May;18(5):437-443. doi: 10.1080/14737140.2018.1451748. Epub 2018 Mar 15.
4
Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients.表柔比星联合顺铂膀胱灌注化疗预防膀胱癌术后复发的多中心随机对照研究
表柔比星联合顺铂膀胱灌注化疗预防膀胱癌术后复发的多中心随机对照研究
表柔比星联合顺铂膀胱灌注化疗预防膀胱癌术后复发的多中心随机对照研究
表柔比星联合顺铂膀胱灌注化疗预防膀胱癌术后复发的多中心随机对照研究
Eur Urol. 2018 Feb;73(2):226-232. doi: 10.1016/j.eururo.2017.06.038. Epub 2017 Jul 10.
5
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.EAU 指南：非肌层浸润性膀胱尿路上皮癌：2016 年更新版。
Eur Urol. 2017 Mar;71(3):447-461. doi: 10.1016/j.eururo.2016.05.041. Epub 2016 Jun 17.
6
Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?经尿道切除术后即刻单次灌注化疗与单纯经尿道切除治疗膀胱 pTa-pT1 期尿路上皮癌的随机对照试验的系统评价和个体患者数据分析：哪些患者从中获益？
Eur Urol. 2016 Feb;69(2):231-44. doi: 10.1016/j.eururo.2015.05.050. Epub 2015 Jun 16.
7
Ablative Intravesical Chemotherapy for Small Recurrent Non-Muscle-Invasive Bladder Cancer: A Prospective Study.消融性膀胱内化疗治疗复发性小非肌层浸润性膀胱癌：一项前瞻性研究。
Urol Int. 2016;96(1):14-9. doi: 10.1159/000377639. Epub 2015 Mar 14.
8
Understanding the use of immediate intravesical chemotherapy for patients with bladder cancer.了解膀胱癌患者即刻膀胱内化疗的应用。
J Urol. 2012 Dec;188(6):2108-13. doi: 10.1016/j.juro.2012.08.044. Epub 2012 Oct 18.
9
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.使用欧洲癌症研究与治疗组织（EORTC）风险表预测Ta T1期膀胱癌个体患者的复发和进展：来自七项EORTC试验的2596例患者的综合分析
Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7. doi: 10.1016/j.eururo.2005.12.031. Epub 2006 Jan 17.
Zotero 插件